World Health Organization Grants Name ‘Seliforant’ to Sensorion’s SENS-111 Treatment


Seliforant (formerly SENS-111) is a first-in-class histamine H4 receptor antagonist candidate selected for the treatment of vertigo of vestibular origin, in development to treat acute unilateral vestibulopathy (AUV), a severe form of vestibular disease

Seliforant is Sensorion’s lead clinical candidate currently in a Phase 2 trial

MONTPELLIER, France, May 03, 2018 (GLOBE NEWSWIRE) -- Sensorion (FR0012596468 – ALSEN), a biotech company specializing in the treatment of inner ear diseases, today announces that the World Health Organization (WHO) has granted the International Non-Proprietary Name (INN), seliforant, to its lead clinical candidate, SENS-111 for the treatment of vertigo of vestibular origin and currently in phase 2 clinical development being investigated for acute unilateral vestibulopathy (AUV), a severe form of vertigo.

We are pleased that the INN division of the WHO has granted the name seliforant to our investigational agent SENS-111,” said Nawal Ouzren, Chief Executive Officer of Sensorion. “This event signals continued progress for our lead clinical program and we look forward to results from the ongoing phase 2 trial, expected in end of this year.”

About Seliforant
Seliforant (formerly SENS-111) is the first representative candidate of the histamine type 4 receptor antagonist class to be tested for the symptomatic treatment of vertigo crises. Displaying a neuromodulation effect of the sensorineural inner ear cell function, seliforant is a small molecule that can be taken orally or via a standard injection, and is currently in a Phase 2 clinical trial, being conducted in the United States, Europe and South Korea.

About Sensorion
Sensorion is a biotech company pioneering novel treatments of inner ear diseases such as severe vertigo, tinnitus or hearing loss. Two products are currently in the clinical development stage: Seliforant (formerly SENS-111) in phase 2 in acute unilateral vestibulopathy (vestibular neuritis), and SENS-401, which has completed a phase 1 trial. The company was founded by Inserm (the French Institute of Health and Medical Research) and is utilizing its pharmaceutical R&D experience and comprehensive technology platform to develop first-in-class easy-to-administer, notably orally active, drugs for treating and preventing hearing loss and the symptoms of bouts of vertigo and tinnitus.

Based in Montpellier, Southern France, Sensorion has received financial support from Bpifrance, through the InnoBio fund, and Inserm Transfert Initiative.

Sensorion has been listed on the Euronext Growth Paris exchange since April 2015.


Nawal Ouzren
Tél : +33 467 207 730
Investor Relations
LifeSci Advisors LLC
Chris Maggos
Tél. : +41 79 367 6254
ISIN : FR0012596468
Mnemonic : ALSEN

Alize RP
Caroline Carmagnol & Wendy Rigal


This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward-looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the Document de référence registration document filed with the Autorité des marchés financiers (AMF- French Financial Market Authority) on July 28, 2016 under n°R.16-069 and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements.

This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.